EuroBiotech: More Articles of Note


> Basilea Pharmaceutica received $54.8 million (€48.9 million) from the Biomedical Advanced Research and Development Authority (BARDA). The Swiss biotech secured the cash to support phase 3 development of its antibiotic ceftobiprole. BARDA committed to give Basilea up to $108 million to support the program last year. And, with Basilea having passed certain milestones, the funding agency has released another tranche of cash. Statement

> Alligator Bioscience moved ATOR-1017 into preclinical development. ATOR-1017 activates a co-stimulatory receptor expressed on T cells to direct immune activity toward tumors. Alligator has teamed up with Sartorius Stedim Cellca and Glycotope Biotechnology to obtain materials for early-phase clinical trials. Release

> Probiodrug posted data from a phase 2a trial of its Alzheimer’s disease candidate PQ912. The 120-patient trial found a significantly higher adverse event-related discontinuation rate and total number of nonadherent patients in the treatment arm. But the principal investigator expressed confidence that the glutaminylcyclase inhibitor is safe and well tolerated. Probiodrug also looked for early signs of efficacy. Statement

> PsiOxus Therapeutics unveiled new facilities on both sides of the Atlantic. The immuno-oncolytic virus player is moving into a 21,000-square-foot facility near Oxford, U.K. And has opened a site in Philadelphia, PA, its first facility outside of its home country. Statement

> TiGenix started a phase 3 trial of its stem cell therapy Cx601. The global trial is intended to give TiGenix the data it needs to win approval in the U.S. TiGenix is currently seeking approval of the drug as a treatment for Crohn’s disease in Europe. Release

> GenSight Biologics posted 96-week data on its Leber’s hereditary optic neuropathy gene therapy GS010. The phase 1/2 data show the improvements in patients with less than two years of vision loss have been sustained over the course of the study. GenSight is testing GS010 in two phase 3 trials that are due to report 48-week data next year. Statement